Boston Scientific Earnings: Q1 Growth, 2026 Outlook Cut

Boston Scientific Corp. (BSX) reported solid organic sales growth and strong margins in Q1 2026 but lowered its full-year revenue and adjusted-EPS guidance, citing headwinds in WATCHMAN, electrophysiology, and urology that narrowed its outlook.

Q1 Results and Revised Guidance

The company announced its Q1 results and published a Financial & Operational Highlights report on April 22, 2026, at 6:30 a.m. ET. Net sales reached $5.203 billion, up 11.6% reported and 9.4% on an operational and organic basis year over year. The quarter included a 220-basis-point foreign-exchange tailwind, equal to $104 million. GAAP net income attributable to Boston Scientific rose to $1.341 billion, or $0.90 per share, compared with $674 million, or $0.45 per share, in the year-ago quarter. Adjusted EPS grew 6% to $0.80, hitting the high end of the company’s prior guidance range, while adjusted operating margin stood at 28%.

These results reflect steady demand across multiple product lines and favorable currency effects. The adjusted-profit performance indicates that product mix and cost discipline supported profitability despite slower growth in some areas.

In the same release, Boston Scientific narrowed its full-year 2026 guidance, projecting net sales growth of 7.0% to 8.5% reported and 6.5% to 8.0% organic, down from earlier targets near 10.5% to 11.5% reported and 10% to 11% organic growth. Adjusted EPS guidance was trimmed to a range of $3.34 to $3.41 from prior estimates. For the second quarter, the company set net sales guidance at 5.5% to 7.5% reported and 5.0% to 7.0% organic, with adjusted EPS expected between $0.82 and $0.84.

Management cited headwinds in the WATCHMAN franchise, electrophysiology, and urology as key factors behind the reduced outlook. Market data show WATCHMAN sales of $506 million, up 19.2% year over year; electrophysiology sales of $905 million, up 24%; urology sales of $646 million, up 2%; and cardiovascular sales of about $3.5 billion. WATCHMAN growth is now expected in the mid-teens for the year, while urology is projected to grow below market rates.

The quarter’s top-line momentum and margin strength highlight operational resilience despite the guidance cut. Adjusted EPS at the high end of the range and the solid margin suggest that cost controls and product mix helped offset slower growth in certain franchises. The revised outlook shifts focus to execution in WATCHMAN, electrophysiology, and urology for the remainder of 2026, with the pace of recovery in these areas critical to Boston Scientific’s ability to regain its earlier growth trajectory.